Davenport & Co’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.97M Sell
120,870
-8,270
-6% -$475K 0.03% 302
2026
Q1
$7.83M Sell
129,140
-13,749
-10% -$802K 0.04% 271
2025
Q4
$7.71M Sell
142,889
-78,379
-35% -$3.77M 0.04% 264
2025
Q3
$9.97M Sell
221,268
-1,910,056
-90% -$89.2M 0.05% 232
2025
Q2
$98.7M Sell
2,131,324
-133,594
-6% -$6.56M 0.54% 62
2025
Q1
$138M Buy
2,264,918
+77,468
+4% +$4.52M 0.8% 30
2024
Q4
$123M Sell
2,187,450
-96,985
-4% -$5.42M 0.7% 36
2024
Q3
$118M Sell
2,284,435
-11,711
-0.5% -$549K 0.67% 44
2024
Q2
$95.4M Sell
2,296,146
-89,337
-4% -$4M 0.58% 58
2024
Q1
$129M Buy
2,385,483
+215,717
+10% +$11M 0.79% 32
2023
Q4
$111M Buy
2,169,766
+234,123
+12% +$12.3M 0.76% 36
2023
Q3
$112M Buy
1,935,643
+664,626
+52% +$40.7M 0.85% 29
2023
Q2
$81.4M Buy
1,271,017
+1,004,088
+376% +$67.3M 0.6% 58
2023
Q1
$18.5M Sell
266,929
-6,145
-2% -$433K 0.14% 140
2022
Q4
$19.6M Sell
273,074
-16,790
-6% -$1.27M 0.16% 134
2022
Q3
$20.6M Sell
289,864
-34,952
-11% -$2.54M 0.18% 117
2022
Q2
$25M Sell
324,816
-20,515
-6% -$1.56M 0.21% 114
2022
Q1
$25.2M Sell
345,331
-32,451
-9% -$2.18M 0.17% 115
2021
Q4
$23.6M Sell
377,782
-1,116,601
-75% -$65.5M 0.15% 121
2021
Q3
$88.4M Buy
1,494,383
+61,521
+4% +$4.05M 0.62% 51
2021
Q2
$95.7M Buy
1,432,862
+35,560
+3% +$2.32M 0.74% 40
2021
Q1
$88.2M Sell
1,397,302
-9,782
-0.7% -$609K 0.83% 39
2020
Q4
$87.3M Sell
1,407,084
-7,401
-0.5% -$455K 0.86% 40
2020
Q3
$85.3M Sell
1,414,485
-34,183
-2% -$2.06M 0.95% 30
2020
Q2
$85.2M Sell
1,448,668
-13,610
-0.9% -$814K 1.04% 27
2020
Q1
$81.5M Sell
1,462,278
-536,718
-27% -$32.8M 1.17% 24
2019
Q4
$128M Buy
1,998,996
+65,483
+3% +$3.75M 1.37% 16
2019
Q3
$89.7M Sell
1,933,513
-19,724
-1% -$927K 1.07% 29
2019
Q2
$88.6M Buy
1,953,237
+479,370
+33% +$22.3M 1.05% 30
2019
Q1
$70.3M Buy
1,473,867
+101,268
+7% +$5.04M 0.88% 38
2018
Q4
$71.3M Sell
1,372,599
-9,767
-0.7% -$525K 0.98% 28
2018
Q3
$85.8M Buy
1,382,366
+12,584
+0.9% +$747K 1% 29
2018
Q2
$75.8M Buy
1,369,782
+200,804
+17% +$10.8M 0.93% 29
2018
Q1
$73.9M Sell
1,168,978
-18,304
-2% -$1.18M 0.91% 31
2017
Q4
$72.8M Sell
1,187,282
-28,943
-2% -$1.81M 0.87% 29
2017
Q3
$77.5M Sell
1,216,225
-12,938
-1% -$755K 0.98% 23
2017
Q2
$68.5M Buy
1,229,163
+82,925
+7% +$4.51M 0.91% 28
2017
Q1
$66.1M Sell
1,146,238
-5,368
-0.5% -$294K 0.94% 21
2016
Q4
$67.3M Buy
1,151,606
+1,032,158
+864% +$56.4M 0.97% 19
2016
Q3
$6.44M Buy
119,448
+21,149
+22% +$1.36M 0.1% 133
2016
Q2
$7.23M Buy
98,299
+3,689
+4% +$261K 0.11% 125
2016
Q1
$6.04M Sell
94,610
-8,867
-9% -$559K 0.09% 129
2015
Q4
$7.12M Buy
103,477
+2,288
+2% +$151K 0.12% 123
2015
Q3
$5.99M Buy
101,189
+8,775
+9% +$557K 0.1% 130
2015
Q2
$6.15M Buy
92,414
+5,932
+7% +$391K 0.1% 140
2015
Q1
$5.58M Buy
86,482
+588
+0.7% +$36.8K 0.09% 143
2014
Q4
$5.07M Buy
85,894
+8,780
+11% +$495K 0.08% 143
2014
Q3
$3.95M Sell
77,114
-8,392
-10% -$419K 0.07% 157
2014
Q2
$4.15M Sell
85,506
-8,680
-9% -$428K 0.07% 155
2014
Q1
$4.89M Buy
94,186
+10,198
+12% +$543K 0.09% 146
2013
Q4
$4.46M Buy
83,988
+1,893
+2% +$96.4K 0.08% 147
2013
Q3
$3.8M Sell
82,095
-7,648
-9% -$336K 0.08% 146
2013
Q2
$4.01M Buy
+89,743
New +$3.9M 0.09% 133

Other funds holding BMY

Davenport & Co's BMY Position: Q2 2026 in Review

Davenport & Co reduced its Bristol-Myers Squibb (BMY) stake by 6.4% in Q2 2026, selling an estimated $475K and leaving 120,870 shares worth $6.97M. The position accounts for 0.03% of the portfolio, ranked #302.

Davenport & Co first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $138M in Q1 2025. 582 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Davenport & Co held 120,870 shares of Bristol-Myers Squibb worth $6.97M as of Q2 2026.
  • Davenport & Co sold 8,270 Bristol-Myers Squibb shares in Q2 2026, an estimated $475K.
  • Bristol-Myers Squibb made up 0.03% of Davenport & Co's portfolio in Q2 2026, its #302 holding.
  • Davenport & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Davenport & Co's Bristol-Myers Squibb position peaked at $138M in Q1 2025.
  • 582 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.